Abcam

from Wikipedia, the free encyclopedia
Abcam plc.

logo
legal form Corporation
ISIN GB00B6774699
founding 1998
Seat Cambridge , UK
management Jonathan S. Milner ( CEO )
Number of employees 650 (2012)
sales $ 157 million (2012)
Branch biotechnology
Website www.abcam.com

Abcam is a UK online retailer of polyclonal and monoclonal antibodies and an increasing number of other basic research reagents that are sold worldwide via the Internet. The exchange-traded company listed on the Alternative Investment Market (AIM) of the London Stock Exchange (LSE) has its headquarters in Milton near Cambridge (England). Antibodies from over 400 different OEM manufacturers were marketed under the Abcam label in fiscal year 2012, generating sales of around US $ 157 million and pre-tax profits of around US $ 62 million. 17% of sales are generated with self-produced antibodies.

history

The company was founded in 1998 by telecommunications entrepreneur David Cleevely and biologists Jonathan Simon Milner and Tony Kouzarides in Cambridge , UK . Jonathan Milner, born in 1965, received his B.sc. at the University of Bath and a PhD from the University of Leicester in 1993 with a genetic analysis on Erwinia Amylovora . He is the author and co-author of 6 scientific articles in Pubmed. While he was working as a post-doc at Kouzarides on the BRCA2 protein at Cambridge University , they came up with the idea of ​​founding the company, according to their own statements, due to the lack of suitable research antibodies and the limited availability of reliable data on the few antibodies available. The company Abcam is a trunk word from (ab) antibody (English for antibodies) and (cam) Cambridge .

Soon after the company was founded in 1998, a website was created. The website was originally a search mask that linked to the various manufacturers. Abcam found out about the most frequently searched antibodies and then contacted the manufacturers themselves and now sold these products under the name Abcam. In order to bridge liquidity bottlenecks and generate cash flow , contract manufacturing for antibodies against certain target proteins for scientific projects was accepted. The antibodies were manufactured externally by a Belgian company and sold through Abcam. The focus and design of the business model on the Internet and e-commerce back in 1998, at a time when the Internet was not really being used by the other antibody manufacturers, gave Abcam a clear competitive advantage, which the company has been able to steadily expand to this day.

In 2012, more than 80% of products were purchased from other manufacturers and repackaged before resale. These products are not tested in our own laboratories. It is important to display data, reviews and ratings on the company website for frequently sold products. The sales price can be increased for these products. It is part of company policy that for cost reasons this is only done to a small extent by employees and for the most part by reviews of customers and data from suppliers. Furthermore, the company does not have a field service.

In late 2007, Abcam bought a system for automated production of monoclonal antibodies from laboratory automation specialist Beckman Coulter . As a result, Abcam was able to produce its own monoclonal antibodies for the first time in 2008.

According to the 2009 report by BioInformatics LLC, Abcam's research antibody market share grew to 10% in 2009 from 5.2% in 2006, making Abcam the second largest supplier behind Santa Cruz Biotechnology .

According to a 2011 Frost & Sullivan online survey of over 1100 The Scientist readers, Abcam was the third most popular research antibody supplier after Sigma-Aldrich and Santa Cruz Biotechnology. The online platform Labome states that in 2012 approx. 8.5% of 10,100 scientific publications examined in the field of biology and medicine had used products from Abcam.

share

The shares have been listed on the LSE's AIM since autumn 2005 and are now tradable on the NASDAQ , Frankfurt and Berlin stock exchanges .

Managing directors

  • CEO, board of directors and supervisory board together 15.82%

Institutional investors with more than 3% equity ownership

  • BlackRock Investment 8.09%
  • Baillie Gifford 7.97%
  • Standard Life Investments 6.07%
  • T. Rowe Price 4.87%
  • William Blair & Company 4.66%
  • Kames capital 3.42%

As of January 2013

Acquisitions

In May 2011, it was announced that Abcam would acquire MitoSciences, founded in 2004 in Eugene, Oregon (US), for US $ 6 million. The company offers approximately 200 reagents and monoclonal antibodies for mitochondrial research and had 2010 sales of US $ 2.1 million with 24 employees.

In September 2011 Abcam acquired Ascent Scientific , founded in Bristol, UK in 2005, for USD 16 million. The company offers approximately 400 reagents and laboratory chemicals for proteome research and had 2010 sales of $ 2.2 million with 23 employees.

In April 2012 it was announced that Abcam was buying Epitomics , a company founded in Burlingame, California (USA) in 2002, for a relatively high amount of USD 155 million in relation to its own sales (2012: USD 157 million). According to its own information, the company offers 4072 rabbit monoclonal antibodies for basic research (RUO) and in-vitro diagnostics (IVD) and had sales of 24 in 2011 with over 200 employees in the vicinity of Shanghai, China and a few in Burlingame, USA . $ 7 million. Before the sale, Epitomics had given up plans to be listed on the Taiwan Stock Exchange in late 2011. As early as 2010, activities in the area of ​​therapeutic antibodies were spun off into the newly founded company Apexigen, Inc. With the takeover of Epitomics, Abcam is now involved in the IVD area in addition to research reagents.

Locations

In addition to the headquarters in Cambridge Science Park in Milton, the company has had production and distribution branches since 2002 in Cambridge (Massachusetts) , (USA), 2004 in Bristol , (GB), 2005 Eugene (Oregon) , (USA), 2006 in Tokyo , (Japan), 2009 in Hong Kong , and San Francisco , CA (USA) and 2012 in Hangzhou (China).

Competitor

Manufacturer of antibodies for research purposes

e-commerce platforms

  • Antibodies-online.de
  • Antibodyresource.com
  • Biocompare.com
  • Linscottsdirectory.com

Web links

Individual evidence

  1. ↑ a b c d Abcam plc Annual Report 2012. (PDF; 6.5 MB) Retrieved January 10, 2013 .
  2. ↑ OEM suppliers. Retrieved January 10, 2013 .
  3. ↑ Founder of Abcam. Archived from the original on November 22, 2012 ; Retrieved January 10, 2013 .
  4. ↑ Bachelor thesis J. Milner. Retrieved January 10, 2013 .
  5. ↑ a b Jonathan Milner - Abcam ( Memento from October 20, 2013 in the Internet Archive )
  6. ^ Pubmed publications J. Milner in Leicester. Retrieved January 10, 2013 .
  7. ^ Pubmed publications by J. Milner in Cambridge. Retrieved January 10, 2013 .
  8. ↑ ab-cam name. Retrieved January 10, 2013 .
  9. ^ Lautaro Vargas: How Abcam set out to become the Amazon of biotech. In: cabume.co.uk. Cambridge Startup Stories, archived from the original on October 19, 2013 ; accessed on February 23, 2016 (English).
  10. ↑ Kirstie Urquhart: Who Wants to Be an Entrepreneur? In: sciencemag.org. Retrieved February 23, 2016 .
  11. ↑ a b c J. Millner 2011 on the Abcam strategy. Retrieved January 11, 2013 .
  12. ↑ Automation boosts production of monoclonal antibodies worldwide. (No longer available online.) In: selectscience.net. SelectScience, archived from the original on March 3, 2016 ; accessed on February 23, 2016 .
  13. ^ Automated system to expand monoclonal production. In: abcam.com. Retrieved February 23, 2016 .
  14. ^ Bill Kelly: Abcam Surges in the Antibody Market. In: gene2drug.com. Lens on the Life Science Market, accessed February 23, 2016 (American English).
  15. ↑ Christi Bird: Antibodies User Survey. In: the-scientist.com. The Scientist, accessed February 23, 2016 .
  16. ↑ Abcam Antibodies. In: labome.com. Archived from the original on March 10, 2015 ; accessed on February 23, 2016 (English).
  17. ↑ Abcam plc IPO. Retrieved January 10, 2013 .
  18. ↑ http://www.abcamppls.com/shareholders.html (link not available)
  19. ↑ Press release MitoSciences takeover. Retrieved January 10, 2013 .
  20. ↑ Press release Abcam MitoSciences takeover. Retrieved January 10, 2013 .
  21. ↑ Press release MitoSciences takeover. Retrieved January 10, 2013 .
  22. ^ Takeover of Ascent Scientific. Retrieved January 10, 2013 .
  23. ^ Takeover of Ascent Scientific. Retrieved January 10, 2013 .
  24. ↑ ABCAM Plc ABC Acquisition ( Memento from November 25, 2015 in the Internet Archive )
  25. ↑ Epitomics sales 2011. Accessed January 10, 2013 .
  26. ↑ Abcam buys Epitomics. Retrieved January 10, 2013 .
  27. ↑ Epitomics spins off Apexigen. Retrieved January 10, 2013 .